| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | 1 | Y | 1 Tissue for MammaPrint testing | 960 | 1108 | 521 | 277 | 125 | 36 | 6 | 11/27/2023 | 390 | 128 |
| 1108 | 521 | 277 | 125 | 36 | 6 | |||||||||
| 2 | Y | 2 SOC Chemotherapy | 197 | 96 | 49 | 20 | 7 | 1 | 11/27/2023 | |||||
| 3 SOC Chemotherapy + Durvalumab | 194 | 96 | 50 | 20 | 5 | 1 | ||||||||
| 391 | 192 | 99 | 40 | 12 | 2 | |||||||||
| S2212-Breast, TNBC, Neoadj Chemo + Pembro | 1 | Y | 1 Carbo + Paclitaxel + Pembro -> AC + Pembro | 2400 | 756 | 390 | 212 | 101 | 29 | 5 | 09/15/2023 | 436 | 158 | |
| 2 Carbo + Docetaxel + Pembro | 757 | 387 | 214 | 105 | 33 | 4 | ||||||||
| 1513 | 777 | 426 | 206 | 62 | 9 | |||||||||
| Yes | A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib | 1 | E | Total Registrations | 55 | 0 | 0 | 0 | 0 | 0 | 03/11/2021 | 460 | 190 | |
| 55 | 0 | 0 | 0 | 0 | 0 | |||||||||
| A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab | 1 | E | Total Registrations | 60 | 28 | 14 | 8 | 5 | 2 | 08/24/2023 | 445 | 189 | ||
| 60 | 28 | 14 | 8 | 5 | 2 | |||||||||
| NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA | 1 | T | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 09/22/2017 | ||||
| 1 | 0 | 0 | 0 | 0 | 0 | |||||||||
| NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | 1 | T | Total Registrations | 7 | 0 | 0 | 0 | 0 | 0 | 06/22/2018 | ||||
| 7 | 0 | 0 | 0 | 0 | 0 | |||||||||
| No | A012303-Breast, HER2+, Shortened Adj | 1 | E | Total Registrations | 5 | 5 | 5 | 4 | 1 | 0 | 03/06/2026 | 70 | 22 | |
| 5 | 5 | 5 | 4 | 1 | 0 | |||||||||
| NRGBR009-Breast, EarlyStg, Adjuvant Chemo | 1 | E | Total Registrations | 54 | 39 | 17 | 7 | 2 | 0 | 01/31/2024 | 515 | 197 | ||
| 54 | 39 | 17 | 7 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 44 | 29 | 13 | 4 | 1 | 0 | 01/31/2024 | |||||
| 44 | 29 | 13 | 4 | 1 | 0 | |||||||||